V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007061 | 10004900 | 1.76 | 82 | null | 2017-01-15 | 2017-02-07 | Hydroxycarbamide | N | N | 10491053 | CETUXIMAB + RT |
| 10007062 | 10004902 | 1.54 | null | Palliative (P) | 2017-11-27 | 2018-03-22 | EC | 02 | null | 10491336 | GEFITINIB |
| 10007063 | 10004903 | 1.78 | 71 | Palliative (P) | 2016-04-11 | 2016-04-28 | Cytarabine HD + Rituximab | N | N | 10491336 | LEAM |
| 10007064 | 10004903 | 1.75 | 61.6 | Palliative (P) | 2017-06-23 | 2017-08-14 | Cisplatin + Modified de Gramont | 02 | N | 10491336 | VEPEMB |
| 10007065 | 10004904 | 1.76 | 83.2 | Palliative (P) | null | 2016-01-06 | CLARITY Trial | 2 | N | 10491628 | CHLVPP |
| 10007066 | 10004904 | 1.79 | 79.4 | Palliative (P) | 2016-12-08 | 2017-01-27 | ECX | N | N | 10491628 | ECX |
| 10007067 | 10004905 | 164.5 | 96.2 | Palliative (P) | 2017-08-11 | 2017-08-25 | Capecitabine + Cisplatin | N | N | 10492185 | VINFLUNINE |
| 10007068 | 10004905 | 1.61 | null | Curative (C) | 2016-10-07 | 2016-10-08 | ECX | N | N | 10492185 | PAZOPANIB |
| 10007069 | 10004905 | null | 62.8 | Neo-adjuvant (N) | 2018-09-09 | 2018-09-10 | Cyclophos + Dex + Lenalidomide | 02 | N | 10492185 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10007070 | 10004907 | null | 67 | Adjuvant (A) | 2017-06-28 | 2017-07-12 | CAPECITABINE + IRINOTECAN | N | N | 10493601 | CETUXIMAB + OXALIPLATIN + MDG |
| 10007071 | 10004909 | 1.63 | 74 | Palliative (P) | null | 2018-08-16 | Pazopanib | N | N | 10493788 | RITUXIMAB + VINBLASTINE |
| 10007072 | 10007472 | 1.58 | 67.6 | Curative (C) | 2017-12-05 | 2017-12-05 | Hydroxycarbamide | 02 | N | 10494053 | IMATINIB |
| 10007073 | 10004910 | 1.69 | 57.2 | Adjuvant (A) | 2017-08-06 | 2017-08-06 | PERTUZUMAB + TRASTUZUMAB | N | N | 10494098 | DABRAFENIB |
| 10007074 | 10008573 | 1.78 | 67.6 | Adjuvant (A) | null | 2017-08-20 | FOCUS4 TRIAL | N | N | 10494453 | ECX |
| 10007075 | 10008573 | 1.76 | 97.7 | Palliative (P) | 2016-05-29 | 2016-06-05 | Fluorouracil+Mitomycin+RT (Bladder) | N | N | 10494453 | CISPLATIN + VINORELBINE + RT |
| 10007076 | 10004913 | 0 | 80.4 | Disease modification (D) | 2019-04-06 | 2019-04-20 | FOCUS4 TRIAL | N | N | 10494722 | MYELOMA XI TRIAL |
| 10007077 | 10004914 | 1.74 | 72 | Disease modification (D) | 2014-10-24 | 2014-11-07 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 02 | N | 10494795 | FLUOROURACIL + MITOMYCIN |
| 10007078 | 10004917 | 1.7 | 80.6 | Neo-adjuvant (N) | 2016-11-05 | 2016-11-05 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | N | 10494984 | METHOTREXATE INTRATHECAL |
| 10007079 | 10004917 | 1.8 | 62 | Palliative (P) | 2017-02-17 | 2017-02-17 | Cisplatin 7 day | 2 | N | 10494984 | RALTITREXED |
| 10007080 | 10004919 | 2 | 62.9 | Palliative (P) | 2017-07-10 | 2017-07-10 | Thalidomide 50mg | 02 | N | 10495054 | DOCETAXEL + NINTEDANIB |
| 10007081 | 10004920 | 1.65 | 76.1 | Curative (C) | 2015-07-15 | 2015-07-22 | Erlotinib | null | null | 10496032 | BORTEZOMIB |
| 10007082 | 10004921 | 1.66 | 82.9 | Palliative (P) | 2016-07-24 | 2016-08-28 | Methotrexate High Dose (3g/m2) | 02 | N | 10496074 | CETUXIMAB |
| 10007083 | 10004921 | 1.62 | 71 | Palliative (P) | 2018-01-15 | 2018-01-15 | ECF | N | N | 10496074 | BEVACIZUMAB + CAPE + OXALIPLATIN |
| 10007084 | 10004922 | 1.68 | 75.3 | Palliative (P) | 2014-04-23 | 2014-05-11 | METHOTREXATE | 02 | N | 10496656 | BOSUTINIB |
| 10007085 | 10004925 | 1.69 | 61.9 | Palliative (P) | 2017-09-23 | 2017-09-25 | CAPECITABINE + CARBOPLATIN | 02 | null | 10496656 | DOCETAXEL + NINTEDANIB |
| 10007086 | 10004927 | 1.77 | 89 | Disease modification (D) | 2016-12-06 | 2017-08-31 | Methotrexate intrathecal | N | N | 10496956 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 10007087 | 10007481 | 1.77 | null | null | 2017-09-21 | 2017-09-21 | ECX | 01 | N | 10498010 | BEXAROTENE |
| 10007088 | 10004930 | null | 96 | Palliative (P) | 2018-06-15 | 2018-06-15 | R Chlorambucil | N | N | 10498592 | AML16 TRIAL |
| 10007089 | 10004932 | 1.73 | 68 | Disease modification (D) | 2017-11-05 | 2017-11-21 | Cytarabine High Dose | 02 | N | 10498611 | CYCLOPHOSPHAMIDE |
| 10007090 | 10004934 | 1.79 | 96.05 | Disease modification (D) | 2018-09-16 | 2018-09-16 | POMALIDOMIDE | N | N | 10498761 | CAPECITABINE + IRINOTECAN |
| 10007091 | 10004934 | 1.75 | 60 | Disease modification (D) | 2018-04-06 | 2018-04-06 | Temozolomide + RT | N | N | 10498761 | AC |
| 10007092 | 10004935 | 1.62 | 70.6 | Palliative (P) | 2017-09-12 | 2017-09-19 | Cisplatin + Vinorelbine (IV) | 2 | N | 10499282 | PERTUZUMAB |
| 10007093 | 10004935 | 1.79 | 70 | Not known (9) | null | 2017-06-23 | Cisplatin + Gemcitabine (D 1 & 8) | 02 | N | 10499282 | CHOP |
| 10007094 | 10004937 | 1.72 | 66 | Disease modification (D) | 2017-05-11 | 2017-05-17 | Erlotinib | N | N | 10501629 | TOPOTECAN |
| 10007095 | 10004938 | 1.62 | 69.4 | Palliative (P) | 2019-01-18 | 2019-02-17 | Hydroxycarbamide | N | N | 10501744 | CAPECITABINE + GEMCITABINE |
| 10007096 | 10004939 | 1.76 | 0 | Palliative (P) | 2016-06-09 | 2016-06-09 | CYTARABINE + FLUDARABINE | 2 | N | 10501772 | CETUXIMAB |
| 10007097 | 10004939 | null | 83.5 | null | 2019-02-22 | 2019-02-22 | Melphalan IV High dose | 02 | N | 10501772 | CAPECITABINE + GEMCITABINE |
| 10007098 | 10004940 | 1.75 | 63.2 | Palliative (P) | 2017-12-27 | 2018-01-03 | BORTEZOMIB + THALIDOMIDE | N | N | 10502066 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10007099 | 10007487 | 1.86 | 70 | Disease modification (D) | 2015-10-28 | 2015-12-02 | Hydroxycarbamide | 02 | null | 10502066 | QUASAR 2 TRIAL |
| 10007100 | 10004944 | null | 92.5 | Palliative (P) | 2015-02-20 | 2015-10-02 | Bortezomib +/- Dexamethasone | 2 | N | 10502096 | CETUXIMAB |
| 10007101 | 10004945 | 1.78 | 66 | null | 2018-05-08 | 2018-08-04 | MaxiCHOP (>Cycle 2) | N | Y | 10502117 | ECX |
| 10007102 | 10004945 | null | 99.9 | null | null | 2018-02-04 | CISPLATIN + VINORELBINE + RT | N | Y | 10502117 | FLUOROURACIL + MITOMYCIN |
| 10007103 | 10004947 | 1.6 | 0 | Palliative (P) | 2017-12-07 | 2017-12-07 | ECX | N | null | 10502231 | PERTUZUMAB + TRASTUZUMAB |
| 10007104 | 10007489 | 164.5 | 63.8 | Palliative (P) | 2014-09-23 | 2014-10-12 | CHLORAMBUCIL + RITUXIMAB | N | N | 10502260 | CARBOPLATIN + RT |
| 10007105 | 10007490 | null | 95 | Disease modification (D) | 2017-12-26 | 2018-01-08 | UKALL14- Ph 2 Induction | N | N | 10502332 | BENDAMUSTINE |
| 10007106 | 10004949 | 1.61 | 58 | Palliative (P) | 2016-07-10 | 2016-07-18 | FEC | 02 | N | 10502333 | CARFILZOMIB |
| 10007107 | 10004951 | null | 52.25 | Disease modification (D) | 2017-08-26 | 2017-10-31 | LANREOTIDE | null | N | 10502474 | CARDAMON TRIAL |
| 10007108 | 10004951 | 1.53 | 69.8 | Disease modification (D) | 2018-04-14 | 2018-06-14 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 02 | N | 10502474 | PERTUZUMAB + TRASTUZUMAB |
| 10007109 | 10008581 | 1.72 | 64 | Adjuvant (A) | 2018-05-04 | 2018-05-14 | TAC | N | N | 10502596 | UKALL2014 |
| 10007110 | 10008581 | 1.66 | 69.6 | Palliative (P) | 2018-07-26 | 2018-09-06 | Cisplatin + Pemetrexed | N | N | 10502596 | PERTUZUMAB + TRASTUZUMAB |